The company generates a 28% free cash flow margin and a 14.4% FCF yield despite a GAAP loss and carries a perfect balance sheet score—but a confirmed downtrend with the 200-day moving average declining at 8.6% per 30 days, a hard technical block, 29% short interest, and a market capitalization below the $1 billion investable threshold create structural barriers that override the cash-flow quality.
Thesis pillars
- Fcf Positive Despite Gaap Loss→Stable
- Confirmed Downtrend Hard Technical Block→Stable
- Persistent Earnings Miss Pattern→Stable
- +1 more pillar — see the Why tab for full reasoning
Certara, Inc. (CERT) Stock Analysis
Recovery setup
Healthcare · Health Information Services
Sell if holding. Analyst target reached at $7.01 — A.R:R is negative (-0.6) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Consecutive earnings misses (3).
Certara, Inc. is a global leader in biosimulation software and consulting services that support Model-Informed Drug Development (MIDD) for the biopharmaceutical industry, with a customer base whose drugs have received 90% or more of all novel FDA approvals from 2014 through... Read more
Sell if holding. Analyst target reached at $7.01 — A.R:R is negative (-0.6) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Consecutive earnings misses (3). Chart setup: Death cross but MACD improving, RSI 79. Score 4.5/10, moderate confidence.
Passes 6/9 gates (positive momentum, clean insider activity, news events none recent, earnings proximity 31d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: speculative.
About Certara, Inc.
About Certara, Inc.
Certara's biosimulation and Model-Informed Drug Development platforms serve more than 2,600 life sciences companies and 20 global drug regulatory agencies, with software licensed by more than 160,000 users; customers of Certara have received 90% or more of all novel FDA drug approvals from 2014 through 2025. The company employs staff in 28 countries — roughly 585 in the U.S., 707 in Europe, and 177 in Asia — and has completed 21 acquisitions since 2013 to expand its Simcyp, Phoenix, Pinnacle 21, and CoAuthor product lines.
Certara earns revenue from software licenses and technology-enabled consulting services spanning biosimulation (Simcyp for mechanistic PBPK modeling, Phoenix for PK/PD analysis), scientific informatics (Chemaxon, acquired 2024), clinical-data standardization (Pinnacle 21), and regulatory writing and submissions (CoAuthor, GlobalSubmit). The company introduced 103 new software applications and upgrades in 2025 alone, reflecting a research-and-development-intensive cost structure, and licenses its software to the FDA, Japan's PMDA, and China's NMPA on annually renewable terms that carry no renewal obligation. Certara's most significant fixed cost is compensation for its highly specialized workforce, which included 414 employees holding PhD or M.D. degrees as of December 31, 2025. Growth depends heavily on customers' own R&D budgets — biopharmaceutical companies spent an estimated $290 billion on R&D in 2025 — making Certara's revenue sensitive to funding cycles, drug-price-control policy such as the Inflation Reduction Act, and consolidation among large pharmaceutical customers that can shrink the total number of software licenses in force.
Show full overview
Certara's business model ties its revenue indirectly to the operational health of the regulatory agencies its customers must satisfy, not just to biopharma R&D spending directly: the 10-K discloses that an Executive Order-driven reorganization cut roughly 3,500 full-time FDA positions beginning April 1, 2025, following a broader 20,000-employee reduction across HHS, with further layoffs implemented July 14, 2025 after litigation reached the Supreme Court. Because Certara's regulatory science and submission-management services depend on predictable FDA guidance, inspections, and review timelines, continued disruption at the FDA — or a prolonged government shutdown — could slow customer drug-development programs and delay the demand Certara would otherwise capture, independent of any change in the underlying science of biosimulation.
See also: Healthcare · Health Information Services
From Certara, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-07-07Recent Developments — Certara, Inc.
Material events (past 30 days)
- 8K Jun 17, 2026 MEDIUM Item 5.02: CFO John E. Gallagher III resigned effective July 14, 2026, to pursue another opportunity, with no disagreement over Certara's operations or financial reporting cited. The Company appointed Faiz Mohammed, SVP Finance and Treasurer since 2018, as Interim CFO and principal financial/accounting officer
Latest news
- NEWS Franklin Covey Cuts Revenue Forecast, Joins Ouster And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session — benzinga Jul 2, 2026 negative
- NEWS Certara Appoints Faiz Mohammed To Serve As Interim CFO — benzinga Jun 17, 2026
- NEWS Certara Reaffirms FY26 Guidance — benzinga Jun 17, 2026
- NEWS Certara CFO John Gallagher To Resign July 14, 2026 — benzinga Jun 17, 2026
- NEWS Craig-Hallum Maintains Hold on Certara, Lowers Price Target to $8 — benzinga May 12, 2026
Generated 2026-07-07T00:51:42Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Material Events(8-K, last 90d)
- 2026-06-17Item 5.02MEDIUMCFO John E. Gallagher III resigned effective July 14, 2026, to pursue another opportunity, with no disagreement over Certara's operations or financial reporting cited. The Company appointed Faiz Mohammed, SVP Finance and Treasurer since 2018, as Interim CFO and principal financial/accounting officer effective July 15, 2026, while a permanent search continues.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $7.01 — A.R:R is negative (-0.6) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Consecutive earnings misses (3). Chart setup: Death cross but MACD improving, RSI 79. Prior stop was $6.63. Score 4.5/10, moderate confidence.
Take-profit target: $7.13 (0.0% upside). Prior stop was $6.63. Stop-loss: $6.63.
Analyst target reached - limited upside remaining; Consecutive earnings misses (3); Negative news sentiment (-1.00).
Certara, Inc. trades at a P/E of N/A (forward 16.8). TrendMatrix value score: 6.8/10. Verdict: Sell.
20 analysts cover CERT with a consensus score of 3.8/5. Average price target: $7.
What does Certara, Inc. do?Certara, Inc. is a global leader in biosimulation software and consulting services that support Model-Informed Drug...
Certara, Inc. is a global leader in biosimulation software and consulting services that support Model-Informed Drug Development (MIDD) for the biopharmaceutical industry, with a customer base whose drugs have received 90% or more of all novel FDA approvals from 2014 through 2025. The company's platforms include the Simcyp mechanistic simulator, the Phoenix PK/PD suite, Pinnacle 21 clinical data tools, and CoAuthor regulatory-writing software, serving more than 2,600 life sciences companies and 20 global drug regulators, and has completed 21 acquisitions since 2013, including Chemaxon in 2024.